tetano
Editor, Senior Moderator
J Gen Virol. 2010 Aug 18. [Epub ahead of print]
Evaluation of an MVA-based candidate pandemic influenza A/H1N1 vaccine in the ferret model.
Kreijtz JH, Suezer Y, Bodewes R, Schwantes A, van Amerongen G, van den Brand J, van Trierum SE, Kuiken T, Fouchier RA, Osterhaus AD, Sutter G, Rimmelzwaan GF.
Erasmus MC;
Abstract
The zoonotic transmissions of highly pathogenic avian influenza viruses of the H5N1 subtype that occur since 1997 have sparked the development of novel influenza vaccines. The advent of reverse genetics technology, cell culture production techniques and novel adjuvants has improved the vaccine strain preparation, the production process and the immunogenicity of the vaccines, respectively and would accelerated the availability of pandemic influenza vaccines. However, there is still room for improvement and alternative vaccine preparations are explored such as viral vectors. Modified Vaccinia virus Ankara (MVA), originally developed as a safe smallpox vaccine can be exploited as a viral vector an d has many favourable properties. Recently we have demonstrated that the use MVA-based vaccine could protect mice and macaques against infection with highly pathogenic influenza viruses of the H5N1 subtype.In the present study, recombinant MVA expressing the HA gene of pandemic influenza A/H1N1 virus was evaluated in the ferret model. A single immunization induced modest antibody responses and afforded only modest protection against the development of severe disease upon infection with a 2009(H1N1) strain. In contrast, two immunizations induced robust antibody responses and protected ferrets from developing severe disease, confirming that MVA is an attractive influenza vaccine production platform.
PMID: 20719991 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20719991
Evaluation of an MVA-based candidate pandemic influenza A/H1N1 vaccine in the ferret model.
Kreijtz JH, Suezer Y, Bodewes R, Schwantes A, van Amerongen G, van den Brand J, van Trierum SE, Kuiken T, Fouchier RA, Osterhaus AD, Sutter G, Rimmelzwaan GF.
Erasmus MC;
Abstract
The zoonotic transmissions of highly pathogenic avian influenza viruses of the H5N1 subtype that occur since 1997 have sparked the development of novel influenza vaccines. The advent of reverse genetics technology, cell culture production techniques and novel adjuvants has improved the vaccine strain preparation, the production process and the immunogenicity of the vaccines, respectively and would accelerated the availability of pandemic influenza vaccines. However, there is still room for improvement and alternative vaccine preparations are explored such as viral vectors. Modified Vaccinia virus Ankara (MVA), originally developed as a safe smallpox vaccine can be exploited as a viral vector an d has many favourable properties. Recently we have demonstrated that the use MVA-based vaccine could protect mice and macaques against infection with highly pathogenic influenza viruses of the H5N1 subtype.In the present study, recombinant MVA expressing the HA gene of pandemic influenza A/H1N1 virus was evaluated in the ferret model. A single immunization induced modest antibody responses and afforded only modest protection against the development of severe disease upon infection with a 2009(H1N1) strain. In contrast, two immunizations induced robust antibody responses and protected ferrets from developing severe disease, confirming that MVA is an attractive influenza vaccine production platform.
PMID: 20719991 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20719991